TTK and neoplasm: In esophageal cancer, MAGE-A, NY-ESO-1, LAGE-1, and TTK are highly expressed, and they can induce specific CTL cells to produce specific killing effect on tumor cells, and some clinical trials have demonstrated that tumor immunotherapy for esophageal cancer patients is effective, which provides a new therapeutic strategy for the treatment of esophageal cancer in the future.